Abstract | BACKGROUND AND PURPOSE: EXPERIMENTAL APPROACH: The effects of 8-week tofogliflozin or losartan treatment on renal and beta-cell function were investigated in db/db mice by quantitative image analysis of glomerular size, mesangial matrix expansion and islet beta-cell mass. Blood glucose, glycated Hb and insulin levels, along with urinary albumin and creatinine were measured KEY RESULTS: CONCLUSIONS AND IMPLICATIONS:
|
Authors | T Nagata, T Fukuzawa, M Takeda, M Fukazawa, T Mori, T Nihei, K Honda, Y Suzuki, Y Kawabe |
Journal | British journal of pharmacology
(Br J Pharmacol)
Vol. 170
Issue 3
Pg. 519-31
(Oct 2013)
ISSN: 1476-5381 [Electronic] England |
PMID | 23751087
(Publication Type: Comparative Study, Journal Article)
|
Copyright | © 2013 The British Pharmacological Society. |
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Benzhydryl Compounds
- Biomarkers
- Blood Glucose
- Glucosides
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin
- Slc5a2 protein, mouse
- Sodium-Glucose Transporter 2
- Sodium-Glucose Transporter 2 Inhibitors
- Losartan
- 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol
|
Topics |
- Albuminuria
(metabolism, prevention & control)
- Angiotensin II Type 1 Receptor Blockers
(pharmacology)
- Animals
- Benzhydryl Compounds
(pharmacology)
- Biomarkers
(blood)
- Blood Glucose
(drug effects, metabolism)
- Diabetes Mellitus, Type 2
(complications, drug therapy, metabolism, physiopathology)
- Diabetic Nephropathies
(etiology, metabolism, physiopathology, prevention & control)
- Disease Models, Animal
- Female
- Glucosides
(pharmacology)
- Glycated Hemoglobin
(metabolism)
- Hypoglycemic Agents
(pharmacology)
- Insulin
(blood)
- Insulin-Secreting Cells
(drug effects, metabolism, pathology)
- Kidney
(drug effects, metabolism, pathology, physiopathology)
- Losartan
(pharmacology)
- Mice
- Sodium-Glucose Transporter 2
(metabolism)
- Sodium-Glucose Transporter 2 Inhibitors
- Time Factors
|